RECEIVED

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

DEC 1 1 2000

In re Application of;

OKURA et al.

Appln. No.: 09/479,868

Filed: January 1, 2000

For: GENOMIC DNA ENCODING A

POLYPEPTIDE CAPABLE OF ...

Box Sequence

TECH CENTER 1699/2990

Examiner: D. JIANG

RECEIVED

Washington, D.C.

December 11, 2000

TECH CENTER 1600/2900

Atty.Docket: OKURA1A

RESPONSE TO NOTICE TO COMPLY WITH SEQUENCE LISTING REQUIREMENTS

Honorable Commissioner for Patents Washington, D.C. 20231

Sir:

In response to the Notice to Comply, dated November 15, 2000, applicants state as follows:

The computer readable form in this application no. 09/479,882 is identical with that filed on June 27, 1997, in application no. 08/884,324, filed June 27, 1997. In accordance with 37 C.F.R. \$1.821(e), please use the last-filed computer readable form filed in that application as the computer readable form for the instant application. It is understood that the Patent and Trademark Office will make the necessary change in application number and filing date for the instant application. A paper copy of the Sequence Listing is included in the originally-filed specification of the instant application.

Respectfully submitted,

BROWDY AND NEIMARK, P.L.L.C. Attorneys for Applicant(s)

Ву

Allen C. Yun

Registration No. 37,971

ACY:pr

Telephone No.: (202) 628-5197 Facsimile No.: (202) 737-3528

Fig. , for tMA () and LA α to collegues the Lagrangian distance (

	_	
	Application No.	Applicant(s)
Notice to Comply	091479862	Takanori Okuraies
	Examiner DONG TOAK	Art Unit DEC 1 1 2000 W
NOTICE TO COMPLY WITH REQU	DONG JIANG	
NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE		
DISCLOSURES		
Applicant must file the items indicated belo	w within the time period set th	ne Office action to which the Notice
is attached to avoid abandonment under 39 provisions of 37 CFR 1.136(a)).	5 U.S.C. § 133 (extensions of	time may be obtained under the
The nucleotide and/or amino acid sequence	e disclosure contained in this	
The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):		
1. This application clearly fails to compl	v with the requirements of 37	C.F.R. 1.821-1.825 Applicant's
attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking		
notice published at 63 FR 29620 (June	1, 1998) and 1211 OG 82 (Ju	ne 23, 1998).
2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence		
Listing as required by 37 C.F.R. 1.821(c).		
3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).		
4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the		
content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."		
5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer		
readable form must be submitted as requ	uired by 37 C.F.R. 1.825(d).	
6. The paper copy of the "Sequence Listi "Sequence Listing" as required by 37 C.F	ng" is not the same as the co	mputer readable from of the
	` ,	
\boxtimes 7. Other: Applicant should follow the for $\widehat{\mathbb{I}}$ led in the parent application be used to crea	mat of the attached sample s ite a CRF in this application.	statement to request that the CRF
Applicant Must Provide:		
☐ An initial or substitute computer readable	form (CRF) copy of the "Sequ	uence Listing".
☐ An initial or substitute paper copy of the "nto the specification.	Sequence Listing", as well as	an amendment directing its entry
A statement that the content of the pa	ner and computer readable	copies are the series and the
pplicable, include no new matter, as require .825(d).	ed by 37 C.F.R. 1.821(e) or 1	.821(f) or 1.821(g) or 1.825(b) or
(4).		RECEIVED
or questions regarding compliance to	these requirements, ple	

- TECH CENTER 1600/2900

For Rules Interpretation, call (703) 308-4216

For CRF Submission Help, call (703) 308-4212

Patentln Software Program Support

Technical Assistance......703-287-0200 To Purchase Patentin Software.....703-306-2600

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR REPLY

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE RECEIVED Art Unit: 1646 In Re Application of: OKURA et al. Examiner: D. JIANG Application No.: 09/479.862 Washington, D C Filed: January 10, 2000 For: GENOMIC DNA ENCODING A POLYPEPTIDE CAPABLE OF Atty.'s Docket: OKURA1A TECH CENTER 1600/2900 Date: December 11, 2000 THE COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C 20231 Sir: Transmitted herewith is an [] Amendment [XX] RESPONSE TO NOTICE TO COMPLY WITH SEQUENCE LISTING REQUIREMENTS in the above-identified application [] Small entity status of this application under 37 CFR 1.9 and 1.27 has been established by a verified statement previously submitted A verified statement to establish small entity status under 37 CFR 1 9 and 1.27 is enclosed. [] No additional fee is required. The fee has been calculated as shown below: SMALL ENTITY OTHER THAN SMALL ENTITY (Col. 1) (Col 3) (Col. 2) CLAIMS HIGHEST NO PRESENT RATE **ADDITIONAL** OR RATE **ADDITIONAL** REMAINING **PREVIOUSLY EXTRA** FEE FEE PAID FOR **AFTER EQUALS** AMENDMENT \$ TOTAL 17 MINUS 20 Ω 9 \$ Х 18 Х INDEP MINUS 3 0 40 \$ 80 \$ \$ FIRST PRESENTATION OF MULTIPLE DEP. CLAIM 135 \$ 270 ADDITIONAL FEE TOTAL OR TOTAL \$ \$ If the entry in Col. 1 is less than the entry in Col. 2, write "0" in Col. 3 If the "Highest Number Previously Paid for" IN THIS SPACE is less than 20, write "20" in this space If the "Highest Number Previously Paid for" IN THIS SPACE is less than 3, write "3" in this space The "Highest Number Previously Paid For" (total or independent) is the highest number found from the equivalent box in Col. 1 of a prior amendment of the number of claims originally filed [XX] Conditional Petition for Extension of Time If any extension of time for a response is required, applicant requests that this be considered a petition therefor [] It is hereby petitioned for an extension of time in accordance with 37 CFR 1 136(a). The appropriate fee required by 37 CFR 1.17 is calculated as shown below Small Entity Other Than Small Entity Response Filed Within Response Filed Within - \$ 55.00 - \$ 110.00 1 1 Second - \$ 195.00 F 1 Second - \$ 390.00 - \$ 890.00 1 Third - \$ 445.00 [] Fourth - \$ 695.00 Fourth - \$ 1390.00 [] Month After Time Period Set Month After Time Period Set [] Less fees (\$_____) already paid for ___ month(s) extension of time on _

[] Please charge my Deposit Account No. 02-4035 in the amount of \$_

[] Credit Card Payment Form, PTO-2038, is attached, authorizing payment in the amount of \$.

[] A check in the amount of \$_ _ is attached (check no)

The Commissioner is hereby authorized and requested to charge any additional fees which may be required in connection with this application or credit any [XX] overpayment to Deposit Account No. 02-4035. This authorization and request is not limited to payment of all fees associated with this communication, including any Extension of Time fee, not covered by check or specific authorization, but is also intended to include all fees for the presentation of extra claims under 37 CFR §1.16 and all patent processing fees under 37 CFR §1.17 throughout the prosecution of the case. This blanket authorization does not include patent issue fees under 37 CFR §1 18

BROWDY AND NEIMARK

Attorneys for Applicant(s)

Βv

Allen C. Yun Registration No 37,971

Facsimile. (202) 737-3528 Telephone (202) 628-5197